CytoDyn Gets $5 Million Private Investment
A private investor put an additional $5 million into the clinical-stage oncology company at $0.24 per common share.
Updated on Nov. 12, 2026 in Biotech

CytoDyn Inc. received a $5 million private investment at $0.24 per common share, with no accompanying warrants. The company said the proceeds will support development of its leronlimab program in colorectal cancer and other solid tumors.
Why it matters
The financing gives the Vancouver, Washington-based oncology company funds to advance clinical and translational research on leronlimab, a CCR5-targeting antibody, in several cancer indications. Its outcome will help determine whether the program can generate evidence for future regulatory pathways.
The private placement was priced at $0.24 per common share for total proceeds of $5 million, with no warrants issued alongside the shares. The investor's identity and the allocation of proceeds across CytoDyn's programs were not disclosed.
The players
CytoDyn Inc.
CytoDyn Inc. is a clinical-stage oncology company headquartered in Vancouver, Washington, that is advancing the CCR5-targeting antibody leronlimab.
The details
CytoDyn completed the investment as a private placement of common shares, and the investor had previously invested in the company. Leronlimab is a humanized monoclonal antibody targeting the CCR5 receptor, and the company is also exploring it in triple-negative breast cancer, pancreatic cancer and glioblastoma.
Timeline
November 12, 2026: CytoDyn announced the $5 million private investment.
May 31, 2026: Fiscal year end covered by the cited Form 10-K.
Roadmap
The investment builds directly on the colorectal cancer work that grew out of CytoDyn's CLOVER study. It places the company's leronlimab development on a path toward broader solid-tumor indications beyond its original focus.
For patients with colorectal cancer or other solid tumors, the investment supports continued clinical development of leronlimab rather than an immediate new treatment option. Any eventual therapy would still require trial results and regulatory review before becoming available.
The takeaway
Funding announcements like this signal investor confidence in early-stage oncology programs but do not by themselves demonstrate clinical benefit. Readers should watch for trial data before drawing conclusions about leronlimab's effectiveness.
Further reading
For more on the research behind this financing, explore Biotech coverage on Wisevoter.
Source note: This article includes information reported by The Manila times.










